Bitcoin to Surge on Japanese Bank Failures: Arthur Hayesby John Darbie 22.06.2024Japanese banking woes signal Bitcoin boom, says Arthur Hayes; massive bond bailouts could lead to stealth money printing and a ...
VR Fitness Game Market Analysis: Trends & Opportunities Exploredby Lilu Anderson 21.06.2024"Explore the booming VR fitness game market, projected to grow from $12.16B in 2023 to $17.73B by 2028, driven by ...
Arthur Hayes Bullish on DOGE and Pendle Amid Crypto Slumpby John Darbie 21.06.2024BitMEX's Arthur Hayes sees bullish potential in Dogecoin (DOGE) and Pendle (PENDLE), investing $8.4M in PENDLE amid a crypto market ...
Nissan Halts Changzhou Plant Amid Persistent China Troublesby Mark Eisenberg 21.06.2024"Nissan halts production at Changzhou plant amid China challenges, impacting 8% of its capacity. Despite market share loss, it stays ...
Australia Stocks Rise; S&P/ASX 200 Gains 0.34%by Mark Eisenberg 21.06.2024Australia's S&P/ASX 200 up 0.34% as top stocks rise, but some fall. Mixed market with key commodity and currency changes. ...
Dollar Steady Amid Fed’s Firmer Stance, Market Jitters Riseby Mark Eisenberg 21.06.2024Dollar holds firm as Fed takes a steady approach, compared to peers. Yen under pressure, BOJ ready to act. Sterling ...
Virtual Reality in Healthcare Market: Trends and Growth Analysisby Lilu Anderson 21.06.2024Discover the latest trends in Virtual Reality in Healthcare, including key drivers, challenges, and growth opportunities from 2024-2030.
Konami’s Avalanche NFT Push: Gaming Revolution or Cash Grab?by John Darbie 21.06.2024Konami’s Resella platform, built on Avalanche, aims to simplify NFT integration in gaming, sparking debate over its impact on gameplay ...
Konami Joins Avalanche: Launches Resella for NFT Tradingby John Darbie 20.06.2024"Konami and Avalanche launch Resella for seamless NFT transactions, integrating blockchain into gaming with yen transactions and zero gas costs."
Esperion Stock Downgraded Amid Merck’s Competitive Pressureby Mark Eisenberg 20.06.2024Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...